X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Partnerships are driving global COVID-19 treatment access

By Megan Van Etten  |    September 22, 2022
Through the constant efforts of U.S. innovators and their global partners, COVID-19 treatments have continued to be distributed to patients around the world — changing the pandemic’s treatment...   Read More

The dangers of expanding the TRIPS waiver

By Megan Van Etten  |    September 19, 2022
World Trade Organization (WTO) members, including the United States, are considering waiving commitments to honor certain intellectual property (IP) rights on COVID-19 treatments, following a harmful...   Read More

ICYMI: New research builds upon growing body of evidence on value of COVID-19 treatments and vaccines

By Andrew Powaleny  |    August 16, 2022
Innovative biopharmaceutical research companies have been dedicated to fighting COVID-19 for over two years. Since the start of the pandemic, America’s biopharmaceutical companies have worked around...   Read More

ICYMI: PhRMA’s Ubl pens op-ed on IP waiver for COVID-19 technologies

By Megan Van Etten  |    July 15, 2022
Member states of the World Trade Organization (WTO) recently agreed to a waiver of intellectual property (IP) protections for COVID-19 vaccines as part of the Trade-Related Aspects of Intellectual...   Read More

ICYMI: Increase in drug-resistant superbugs during COVID-19 highlights need for policy reforms to address antimicrobial resistance

By Andrew Powaleny  |    July 14, 2022
A new report released by the U.S. Centers for Disease Control and Prevention (CDC) shows the number of antimicrobial-resistant (AMR) infections rose dramatically during the first year of the COVID-19...   Read More

COVID-19 vaccines and treatments helped save millions of lives and billions in health care costs

By John Corea  |    July 7, 2022
As the world braves year three of the COVID-19 pandemic and confronts a virus that continues to evolve and challenge us, we’ve come a long way in how we combat this ongoing threat. Since the start of...   Read More

ICYMI: Antimicrobial resistance spotlighted as growing public health threat

By Andrew Powaleny  |    July 6, 2022
On June 28, PhRMA Chief Operating Officer Lori Reilly joined Executive Director of CARB-X, Kevin Outterson, Esq., and Interim Secretariat Lead of the Global Antimicrobial Resistance (AMR) R&D Hub,...   Read More

Intellectual Property waiver on COVID-19 innovation is unnecessary and harmful

By Megan Van Etten  |    May 23, 2022
In two years, biopharmaceutical companies have gone from zero to 13 billion COVID-19 vaccine doses produced. They’ve worked across the industry and on every continent to meet the global demand for...   Read More

ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19

By Andrew Powaleny  |    May 13, 2022
This week, PhRMA sponsored The Washington Post’s event, Coronavirus: Lessons of the Pandemic, where PhRMA president and CEO Stephen J. Ubl shared crucial lessons learned from the pandemic on how to...   Read More

ICYMI: PhRMA COO Lori Reilly spotlights efforts to improve health care in 2022 and beyond

By Emilie Signora  |    May 9, 2022
The COVID-19 pandemic has made clear how important a stable health care system is to the American people, both during times of crisis and beyond. Patients deserve sustainable, patient-centered...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates